1. age below 18 years 2. patients who do not want or can fulfill the necessary home isolation for at least 14 days 3. chronic clinical conditions, severe or not compensated, such as: insulin-dependent diabetes (types 1 or 2); uncontrolled hypertension, lung disease such as asthma or copd; hematological and liver diseases, chronic kidney disease in advanced stage (grades 3, 4 and 5), metabolic disorders and immunosuppression 4. use of any medication with potential interaction with cbd (such as chloroquine, clobazan, warfarin, or valproic acid) or history of undesirable reactions prior to the use of this cannabinoid 5. inability to use oral medication 6. pregnancy or lactation 7. history of alcohol or drug addiction 8. smoking in the last three years 9. marijuana use in the last three months 10. inability to cooperate with researchers due to cognitive impairment or mental state 11. patients with severe forms of sars-cov-2, (on screening, inclusion or initial visit)

1. age below 18 years 2. patients who do not want or can fulfill the necessary home isolation for at least 14 days 3. chronic clinical conditions, severe or not compensated, such as: insulin-dependent diabetes (types 1 or 2); uncontrolled hypertension, lung disease such as asthma or copd; hematological and liver diseases, chronic kidney disease in advanced stage (grades 3, 4 and 5), metabolic disorders and immunosuppression 4. use of any medication with potential interaction with cbd (such as chloroquine, clobazan, warfarin, or valproic acid) or history of undesirable reactions prior to the use of this cannabinoid 5. inability to use oral medication 6. pregnancy or lactation 7. history of alcohol or drug addiction 8. smoking in the last three years 9. marijuana use in the last three months 10. inability to cooperate with researchers due to cognitive impairment or mental state 11. patients with severe forms of sars-cov-2, (on screening, inclusion or initial visit)

age below 18 years patients who do not want or can fulfill the necessary home isolation for at least 14 days chronic clinical conditions, severe or not compensated, such as: insulin-dependent diabetes (types 1 or 2); uncontrolled hypertension, lung disease such as asthma or copd; hematological and liver diseases, chronic kidney disease in advanced stage (grades 3, 4 and 5), metabolic disorders and immunosuppression use of any medication with potential interaction with cbd (such as chloroquine, clobazan, warfarin, or valproic acid) or history of undesirable reactions prior to the use of this cannabinoid inability to use oral medication pregnancy or lactation history of alcohol or drug addiction smoking in the last three years marijuana use in the last three months inability to cooperate with researchers due to cognitive impairment or mental state patients with severe forms of sars-cov-2, (on screening, inclusion or initial visit)

age below 18 years patients who do not want or can fulfill the necessary home isolation for at least 14 days chronic clinical conditions, severe or not compensated, such as: insulin-dependent diabetes (types 1 or 2); uncontrolled hypertension, lung disease such as asthma or copd; hematological and liver diseases, chronic kidney disease in advanced stage (grades 3, 4 and 5), metabolic disorders and immunosuppression use of any medication with potential interaction with cbd (such as chloroquine, clobazan, warfarin, or valproic acid) or history of undesirable reactions prior to the use of this cannabinoid inability to use oral medication pregnancy or lactation history of alcohol or drug addiction smoking in the last three years marijuana use in the last three months inability to cooperate with researchers due to cognitive impairment or mental state patients with severe forms of sars-cov-2, (on screening, inclusion or initial visit)

1. age below 18 years 2. patients who do not want or can fulfill the necessary home isolation for at least 14 days 3. chronic clinical conditions, severe or not compensated, such as: insulin-dependent diabetes (types 1 or 2); uncontrolled hypertension, lung disease such as asthma or copd; hematological and liver diseases, chronic kidney disease in advanced stage (grades 3, 4 and 5), metabolic disorders and immunosuppression 4. use of any medication with potential interaction with cbd (such as chloroquine, clobazan, warfarin, or valproic acid) or history of undesirable reactions prior to the use of this cannabinoid 5. inability to use oral medication 6. pregnancy or lactation 7. history of alcohol or drug addiction 8. smoking in the last three years 9. marijuana use in the last three months 10. inability to cooperate with researchers due to cognitive impairment or mental state 11. patients with severe forms of sars-cov-2, (on screening, inclusion or initial visit)

1. age below 18 years 2. patients who do not want or can fulfill the necessary home isolation for at least 14 days 3. chronic clinical conditions, severe or not compensated, such as: insulin-dependent diabetes (types 1 or 2); uncontrolled hypertension, lung disease such as asthma or copd; hematological and liver diseases, chronic kidney disease in advanced stage (grades 3, 4 and 5), metabolic disorders and immunosuppression 4. use of any medication with potential interaction with cbd (such as chloroquine, clobazan, warfarin, or valproic acid) or history of undesirable reactions prior to the use of this cannabinoid 5. inability to use oral medication 6. pregnancy or lactation 7. history of alcohol or drug addiction 8. smoking in the last three years 9. marijuana use in the last three months 10. inability to cooperate with researchers due to cognitive impairment or mental state 11. patients with severe forms of sars-cov-2, (on screening, inclusion or initial visit)